The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with diabetes.

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

DexCom, Inc. DXCM recently announced the FDA clearance for its 15-day wear G7 Continuous Glucose Monitoring (CGM) system, the ...

Now the longest lasting and most accurate CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes. Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is ...

This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose Monitoring System, marking a significant advancement in diabetes management ...

DexCom (DXCM) announced the FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for people over the age of 18 with ...

“The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “By listening to the needs of ...

(NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous ...